1[11]Powell MF, Grey H, Gaeta F, et al. improved induction of melanima reactive CTL with peptide reactive in different biologic media[J] .J Pharm Sci, 1992,81(8):731 - 735.
2[12]Van Regenmortel MH, Muller S. D-peptides as immunogens and diagnostic reagents [J]. Curr Opin Biotechnol, 1998,9(4) :377 - 382.
3[13]Brinckerhoff LH, Kalashnikov VV, Thompson LW, et al.Terminal modifictioninhibit proteolytic degradation of an immunogenic MART-1 (27-35) peptide :implication for peptide vaccines[J]. Int J Cancer, 1999,83(3) :326 - 334.
4[14]Ayyoub M, Mazarguil H, Monsarrat B, et al. A structurebased approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells[J] .J Biol Chem, 1999,274(15) :10 227 - 10 234.
5[16]Reynolds SR, Oratz R, Shapiro RL, et al. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine[J]. Int J Cancer, 1997,72(6) :972 - 976.
6[3]Parkhurst MR, Salgaller MI, Southwood S,et al. Improve induction of melanima-reactive CTL with peptide from the melanoma antigen gp100 modified at HLA-A * 0201-binding residues[J]. J Immunol, 1996, 157(6) :2 539- 2 548.
7[4]Steven A, Rosenberg G, James C, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [ J ]. Nature Medicine, 1998,4(3): 321 - 327.
8[5]Dudley ME, Nishimura MI, Holt AK, et al. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response[J] .J Immunother, 1999,22(4) :288 - 298.
9[6]Zaremba S, BarzagaE, Zhu M, et al.ldentification of an enhanccr agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen [ J ]. Cancer Res, 1997,57 (20):4 570 - 4 577.
10[8]Tam JP.Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system[J].Natl Acad Sci USA, 1988,85(15) :5 409-5 413.
